Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 38, Issue 2, 2006, Pages 149-156

  Min, C K ^a,b   Kim, S Y ^a,b   Lee, M J ^b   Eom, K S ^a,b   Kim, Y J ^a,b   Kim, H J ^a,b   Lee, S ^a,b   Cho, S G ^a,b   Kim, D W ^a,b   Lee, J W ^a,b   Min, W S ^a,b   Kim, C C ^a,b   Cho, C S ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Acute graft versus host disease; Allogeneic stem cell transplantation; Transplant related mortality; Vascular endothelial growth factors (VEGF)

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; VASCULOTROPIN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLUSTER ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; OPPORTUNISTIC INFECTION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RELAPSE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; CLUSTER ANALYSIS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745755637     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705410     Document Type: Article

References (38)

1. Devine SM, Adkins DR, Khoury H, Brown RA, Vij R, Blum W et al. Recent advances in allogeneic hematopoietic stem-cell transplantation. J Lab Clin Med 2003; 141: 7-32.
2. Wingard JR. Opportunistic infections after blood and marrow transplantation. Transpl Infect Dis 1999; 1: 3-20.
3. Takatsuka H, Takemoto Y, Yamada S, Wada H, Tamura S, Fujimori Y et al. Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transplant 2000; 26: 419-426.
4. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American college of chest physician/society of critical care medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
5. Chen X, Christou NV. Relative contribution of endothelial cell and polymorphonuclear neutrophil activation in their interactions in systemic inflammatory response syndrome. Arch Surg 1996; 131: 1148-1153.
6. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217-239.
7. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
8. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180: 341-346.
9. Selvaraj SK, Giri RK, Perelman N, Johnson C, Malik P, Kalra VK. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003; 102: 1515-1524.
10. Iyer S, Leonidas DD, Swaminathan GJ, Maglione D, Battisti M, Tucci M et al. The crystal structure of human placenta growth factor-1 (P1GF-1), an angiogenic protein, at 2.0 A resolution. J Biol Chem 2001; 276: 12153-12161.
11. Lunn RA, Sumar N, Bansal AS, Treleaven J. Cytokine profiles in stem cell transplantation: Possible use as a predictor of graft-versus-host disease. Hematology 2005; 10: 107-114.
12. Min CK, Kim DW, Lee JW, Han CW, Min WS, Kim CC. Supplemental peripheral blood stem cells to decrease marrow rejection in adult patients with severe aplastic anemia. Am J Hematol 2002; 69: 15-22.
13. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
14. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005; 35: 1089-1093.
15. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
16. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
17. Yoo JH, Choi SM, Lee DG, Choi JH, Shin WS, Min WS et al. Prognostic factors influencing infection-related mortality in patients with acute leukemia in Korea. J Korean Med Sci 2005; 20: 31-35.
18. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
19. Fisher DC, Sherrill GB, Hussein A, Rubin P, Vredenburgh JJ, Elkordy M et al. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transplant 1996; 18: 193-198.
20. Choi SM, Lee DG, Choi JH, Yoo JH, Kim YJ, Park SH et al. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: A single-center experience in Korea. Int J Hematol 2005; 81: 69-74.
21. Frantz S, Vincent KA, Feron O, Kelly RA. Innate immunity and angiogenesis. Circ Res 2005; 96: 15-26.
22. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
23. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 1994; 269: 6271-6274.
24. Min CK, Lee WY, Min DJ, Lee DG, Kim YJ, Park YH et al. The kinetics of circulating cytokines including IL-6, TNF-α, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 935-940.
25. Takatsuka H, Takemoto Y, Okamoto T, Fujimori Y, Tamura S, Wada H et al. Adult respiratory distress syndrome-like disorders after allogeneic bone marrow transplantation. Transplantation 1999; 68: 1343-1347.
26. Takatsuka H, Takemoto Y, Okamoto T, Fujimori Y, Tamura S, Wada H et al. Thrombotic microangiopathy following allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24: 303-306.
27. Takatsuka H, Takemoto Y, Okamoto T, Fujimori Y, Tamura S, Wada H et al. Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation. Bone Marrow Transplant 1999; 24: 1005-1007.
28. Yamada S, Takatsuka H, Takemoto Y, Okamoto T, Fujimori Y, Tamura S et al. Association of cytomegalovirus interstitial pneumonitis with HLA-type following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 861-865.
29. Kim DH, Sohn SK, Jeon SB, Back JH, Kim JG, Lee NY et al. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. Bone Marrow Transplant 2006; 37: 101-108.
30. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998; 80: 171-175.
31. Salgado R, Benoy I, Bogers J, Weytjens R, Vermeulen P, Dirix L et al. Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study. Angiogenesis 2001; 4: 37-43.
32. Kirito K, Kaushansky K. Thrombopoietin stimulates vascular endothelial cell growth factor (VEGF) production in hematopoietic stem cells. Cell Cycle 2005; 4: 1729-1731.
33. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004; 10: 1095-1103.
34. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575-581.
35. Boissel N, Rousselot P, Raffoux E, Cayuela JM, Maarek O, Charron D et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 2004; 18: 1656-1661.
36. Bae DG, Gho YS, Yoon WH, Chae CB. Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J Biol Chem 2000; 275: 13588-13596.
37. Schots R, Van Riet I, Othman TB, Trullemans F, De Waele M, Van Camp B et al. An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 30: 441-446.
38. Bacigalupo A, Oneto R, Bruno B, Soracco M, Lamparelli T, Gualandi F et al. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): Blood urea nitrogen (BUN) and bilirubin. Bone Marrow Transplant 1999; 24: 653-659.